ESC Guidelines on the Diagnosis and Treatment of Peripheral Artery Diseases
By M. Tendera, V. Aboyans, M. Bartelink, I. Baumgartner, Denis L. Clement, Jean-Philippe Collet, A. Cremonesi, M. De Carlo, R. Erbel, F. Fowkes and 11 more. 2012
1,285 citations recorded by the source corpus.
Subfields: Pulmonary and Respiratory Medicine, Rheumatology, Urology
View Paper: https://www.semanticscholar.org/paper/0adc721960150725f2c60f3e02a196fb71c5e3f1
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pulmonary and Respiratory Medicine
In Rheumatology
Citations in the corpus
- Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. (2018, neutral): “By contrast, the primary outcome in the rivaroxaban alone group was not significantly superior to that seen in the aspirin alone group (149 [6”
- 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. (2016, background): “The aorta is often included in the term.(405) PAD is a common manifestation of atherosclerosis, and such patients are at elevated risk of coronary events, with PAD representing an independent risk factor for MI and CV death.”